New Research Released on GeoVax Labs, Inc. (GOVX-OTC)

Posted by Karen Goldfarb

June 19, 2017 at 4:55 PM

An Executive Informational Overview (EIO) is now available on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC). The EIO is a 80-page report detailing GeoVax's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Download GeoVax Report 

Read More

Topics: geovax, vaccines, zika, malaria, aids/hiv, hemorragic fever, hbv, immunotherapy

May 2017 Update Released on Aeterna Zentaris (AEZS)

Posted by Karen Goldfarb

May 15, 2017 at 2:59 PM

Crystal Research Associates has released an 11-page Quarterly Update on specialty biopharmaceutical company, Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX). The Update specifically details Aeterna's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. 

  Download Update

Read More

Topics: AEZS

April 2017 Update Released on Aeterna Zentaris (AEZS)

Posted by Karen Goldfarb

April 5, 2017 at 1:33 PM

Crystal Research Associates has released an 11-page Quarterly Update on specialty biopharmaceutical company, Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX). The Update specifically details Aeterna's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. 

 

 Download Update

Read More

Topics: AEZS

New Research Released on Avivagen Inc. (VIV-TSX.V)

Posted by Karen Goldfarb

March 7, 2017 at 12:41 PM

An Executive Informational Overview (EIO) is now available on pharmaceutical company, Avivagen Inc. (VIV-TSX.V). The EIO is a 56-page report detailing Avivagen's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Download Avivagen Report

Read More

February 2017 Update Released on Aeterna Zentaris (AEZS)

Posted by Karen Goldfarb

February 27, 2017 at 2:56 PM


Crystal Research Associates has released a 10-page Quarterly Update on specialty biopharmaceutical company, Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX). The Update specifically details Aeterna's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. 

Download Update

 

Read More

Topics: AEZS

MagneGas Signs Definitive Agreements for $2.65 Million Equipment Sale to German Company

Posted by Karen Goldfarb

January 5, 2017 at 10:31 AM


As Largest Single Sale in MagneGas History, MagneGas Signs Definitive Agreements for $2.65 mm of Equipment to German Company

MagneGas announced that it has entered into its largest equipment sale to date with the signing of definitive agreements to manufacture and deliver certain equipment and supplies to a German-based company. Under the terms of this Agreement, for which MagneGas will receive $2.65 million, MagneGas will supply MagnesGas2® fuel and cylinders and manufacture and deliver (1) A 300KW stationary Gasification system; (2) A 100KW mobile Sterilization system; (3) 250 cylinders full of MagneGas2®; and (4) 50 MagneGas regulators.  

A deposit of $25,000 has been received, with progress payments totaling $2.625 million to be paid over the course of the manufacturing and delivery of the various systems.  The first payment of $1.35 million is due in 90 days with progress payments due thereafter, with set construction and delivery milestones. The German company has stated that it may be interested in negotiating to purchase several additional systems for multiple markets.  

The German company expects to initially utilize the Gasification system to produce MagneGas2® fuel to sell into the German market with the potential for other markets coming online in the future.  The Sterilization system is expected be used for demonstrations and small service contracts with the goal of entering the agriculture and municipal wastewater treatment markets in Germany.

 Research Available on MagenGas

Our most recently published Executive Informational Overview (EIO) on MageGas Corporation is available below for download. This a 68-page report details MagneGas' business, novel technology and product development, market opportunities, competition, financials, risks, and more.

Read More

Topics: magnegas

Sir Gregory Winter Appointed as Interim Chair of Biosceptre Int'l

Posted by Karen Goldfarb

December 16, 2016 at 3:20 PM

Announces Appointment of Independent Director Sir Gregory Winter as Chair of the Board of Directors

Biosceptre announced that has appointed Sir Gregory Winter as Chair of the Biosceptre Board of Directors. Sir Gregory has led the Scientific Advisory Board of Biosceptre for over 4 years and joined the Board of Directors as a non-executive director in May 2016. Sir Gregory Winter is Master of Trinity College Cambridge and was a past member of the Medical Research Council’s Laboratory of Molecular Biology (LMB), serving as both a Head of Division and as Deputy (and Acting) Director.

Sir Gregory has developed technology to make humanized antibodies and human antibodies in bacteria. A number today's available therapeutic antibodies were developed using methods devised by Sir Gregory. Sir Gregory has unique biotechnology industry experience, being a Founder and Director of Cambridge Antibody Technology (acquired by AstraZeneca), of Domantis (acquired by GlaxoSmithkline) and currently of Bicycle Therapeutics Limited.

Sir Gregory was elected a Fellow of the Royal Society (FRS) in 1990 and awarded the Royal Medal by the society in 2011 for his pioneering work in protein engineering and therapeutic monoclonal antibodies, and his contributions as an inventor and entrepreneur. He has also won several international awards including the King Faisal International Prize for Medicine, the Cancer Research Institute William B. Coley Award and the Canada Gairdner International Award. Sir Gregory was appointed Knight Bachelor in 2004.

Research Available on Biosceptre

Our most recently published Executive Informational Overview (EIO) on Biosceptre International Ltd is available below for download. This a 52-page report details Biosceptre's business, novel technology and product development, market opportunities, competition, financials, risks, and more.

Read More

Topics: Biosceptre

New Research Released on Hemispherx Biopharma $HEB

Posted by Laura Swartz

November 28, 2016 at 8:51 PM

An Executive Informational Overview (EIO) is now available on specialty pharmaceutical company, Hemispherx Biopharma, Inc. (HEB-NYSE). The EIO is a 60-page report detailing Hemispherx's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More

Topics: HEB

New Research Released on Ceapro Inc. $CZO

Posted by Laura Swartz

November 13, 2016 at 3:52 PM

An Executive Informational Overview (EIO) is now available on a revenue-generating Canadian biotechnology company, Ceapro Inc. (CZO-TSX.V). The EIO is a 64-page report detailing Ceapro's business, products and pipeline, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More

Topics: CZO

New Research Released on MagneGas Corp. $MNGA

Posted by Laura Swartz

November 1, 2016 at 8:26 PM

An Executive Informational Overview (EIO) is now available on an alternative energy company, MagneGas Corp. (MNGA-NASDAQ). The EIO is a 68-page report detailing MagneGas' business strategy, products, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More

Topics: MNGA

September 2016 Update Released on Aeterna Zentaris (AEZS)

Posted by Laura Swartz

September 26, 2016 at 9:13 PM

Crystal Research Associates has released a 16-page Quarterly Update on specialty biopharmaceutical company, Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX). The Update specifically details Aeterna's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. 

Read More

Topics: AEZS

UPDATE: Four Recent Milestones for Diagnostics Company SpectraScience (SCIE)

Posted by Laura Swartz

September 15, 2016 at 2:14 PM

  • Up to 80% of colorectal biopsies performed are subsequently identified as normal, non-cancerous tissue. Incorporating an optical biopsy, such as WavSTAT4, before performing an invasive physical biopsy reduces risks to patients by eliminating many unnecessary procedures and may lead to a healthcare cost savings of over $1 billion in the U.S. alone.

  • SpectraScience is working to diagnose “pre-cancers”—suspect tissue or areas in the body before it becomes cancerous. Tissue that WavSTAT4 finds to be precancerous (or cancerous) returns a red “suspect” icon. Unlike the traditional method of visual inspection, there is no ambiguity to the result and no need for physician interpretation.

  • Major 2016 corporate developments include a strategic acquisition, research publication, and development of an international sales infrastructure enabling the start of device sales in the Middle East.

Read More

Topics: SpectraScience

Two New Slide Presentations: Ra Medical Systems and Biosceptre International

Posted by Laura Swartz

September 8, 2016 at 2:37 PM

Crystal Research Associates has recently released Executive Informational Overview (EIO) reports on both Ra Medical Systems, Inc., a profitable medical device company commercializing a new laser system for vascular diseases, and Biosceptre International Ltd., a development-stage immune-oncology company that has identified a new molecular target for cancer treatments.

We have just published a new set of slides that summarize the key elements of each of these companies, from business and product overviews to market sizes and growth strategies.

Read More

Topics: Ra Medical, Biosceptre

New Research Released on Ra Medical Systems, Inc.

Posted by Laura Swartz

August 31, 2016 at 3:41 PM

An Executive Informational Overview (EIO) is now available on a closely held medical device company, Ra Medical Systems, Inc. The EIO is a 56-page report detailing Ra Medical's business strategy, products, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More

Topics: Ra Medical

New Research Released on Biosceptre Int'l Ltd.

Posted by Laura Swartz

July 27, 2016 at 12:28 PM

An Executive Informational Overview (EIO) is now available on a closely held, UK-based, biotech research and development company called Biosceptre International Ltd. The EIO released Tuesday is a 52-page report detailing Biosceptre's business, novel technology and product development, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More

Topics: Biosceptre

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic